BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 35109853)

  • 1. Mutational signatures reveal ternary relationships between homologous recombination repair, APOBEC, and mismatch repair in gynecological cancers.
    Farmanbar A; Firouzi S; Kneller R; Khiabanian H
    J Transl Med; 2022 Feb; 20(1):65. PubMed ID: 35109853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational signatures reveal mutual exclusivity of homologous recombination and mismatch repair deficiencies in colorectal and stomach tumors.
    Farmanbar A; Kneller R; Firouzi S
    Sci Data; 2023 Jul; 10(1):423. PubMed ID: 37393385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy
    Denkert C; Untch M; Benz S; Schneeweiss A; Weber KE; Schmatloch S; Jackisch C; Sinn HP; Golovato J; Karn T; Marmé F; Link T; Budczies J; Nekljudova V; Schmitt WD; Stickeler E; Müller V; Jank P; Parulkar R; Heinmöller E; Sanborn JZ; Schem C; Sinn BV; Soon-Shiong P; van Mackelenbergh M; Fasching PA; Rabizadeh S; Loibl S
    Ann Oncol; 2021 Apr; 32(4):500-511. PubMed ID: 33418062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
    Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
    Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
    Barroso-Sousa R; Jain E; Cohen O; Kim D; Buendia-Buendia J; Winer E; Lin N; Tolaney SM; Wagle N
    Ann Oncol; 2020 Mar; 31(3):387-394. PubMed ID: 32067680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated molecular profile of endometrioid ovarian cancer.
    Pierson WE; Peters PN; Chang MT; Chen LM; Quigley DA; Ashworth A; Chapman JS
    Gynecol Oncol; 2020 Apr; 157(1):55-61. PubMed ID: 32139151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two main mutational processes operate in the absence of DNA mismatch repair.
    Németh E; Lovrics A; Gervai JZ; Seki M; Rospo G; Bardelli A; Szüts D
    DNA Repair (Amst); 2020 May; 89():102827. PubMed ID: 32126497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays.
    Krumm N; Khasnavis NS; Radke M; Banda K; Davies HR; Pennil C; McLean K; Paulson VA; Konnick EQ; Johnson WC; Huff G; Nik-Zainal S; Swisher EM; Lockwood CM; Salipante SJ
    JCO Precis Oncol; 2023 May; 7():e2200720. PubMed ID: 37196218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
    Börcsök J; Diossy M; Sztupinszki Z; Prosz A; Tisza V; Spisak S; Rusz O; Stormoen DR; Pappot H; Csabai I; Brunak S; Mouw KW; Szallasi Z
    Clin Cancer Res; 2021 Jul; 27(13):3734-3743. PubMed ID: 33947694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy.
    Hatakeyama K; Nagashima T; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Serizawa M; Maruyama K; Naruoka A; Akiyama Y; Urakami K; Kusuhara M; Mochizuki T; Yamaguchi K
    Cancer Sci; 2019 Aug; 110(8):2620-2628. PubMed ID: 31152682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    Takamatsu S; Brown JB; Yamaguchi K; Hamanishi J; Yamanoi K; Takaya H; Kaneyasu T; Mori S; Mandai M; Matsumura N
    JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34423229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.
    Mutter RW; Riaz N; Ng CK; Delsite R; Piscuoglio S; Edelweiss M; Martelotto LG; Sakr RA; King TA; Giri DD; Drobnjak M; Brogi E; Bindra R; Bernheim G; Lim RS; Blecua P; Desrichard A; Higginson D; Towers R; Jiang R; Lee W; Weigelt B; Reis-Filho JS; Powell SN
    J Pathol; 2017 Jun; 242(2):165-177. PubMed ID: 28299801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
    Beinse G; Just PA; Le Frere Belda MA; Laurent-Puig P; Jacques S; Koual M; Garinet S; Leroy K; Delanoy N; Blons H; Gervais C; Durdux C; Chapron C; Goldwasser F; Terris B; Badoual C; Taly V; Bats AS; Borghese B; Alexandre J
    Br J Cancer; 2022 Oct; 127(6):1123-1132. PubMed ID: 35752712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases.
    Sun J; Wang C; Zhang Y; Xu L; Fang W; Zhu Y; Zheng Y; Chen X; Xie X; Hu X; Hu W; Zheng J; Li P; Yu J; Mei Z; Cai X; Wang B; Hu Z; Shu Y; Shen H; Gu Y
    Nat Commun; 2019 Jul; 10(1):3190. PubMed ID: 31320627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
    Vanderstichele A; Busschaert P; Olbrecht S; Lambrechts D; Vergote I
    Eur J Cancer; 2017 Nov; 86():5-14. PubMed ID: 28950147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.
    Moore GM; Powell SN; Higginson DS; Khan AJ
    Breast Cancer Res Treat; 2022 Apr; 192(3):649-653. PubMed ID: 35092538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The topography of mutational processes in breast cancer genomes.
    Morganella S; Alexandrov LB; Glodzik D; Zou X; Davies H; Staaf J; Sieuwerts AM; Brinkman AB; Martin S; Ramakrishna M; Butler A; Kim HY; Borg Å; Sotiriou C; Futreal PA; Campbell PJ; Span PN; Van Laere S; Lakhani SR; Eyfjord JE; Thompson AM; Stunnenberg HG; van de Vijver MJ; Martens JW; Børresen-Dale AL; Richardson AL; Kong G; Thomas G; Sale J; Rada C; Stratton MR; Birney E; Nik-Zainal S
    Nat Commun; 2016 May; 7():11383. PubMed ID: 27136393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy.
    Silva SB; Wanderley CWS; Colli LM
    Front Immunol; 2022; 13():826577. PubMed ID: 35211121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences.
    Leskela S; Romero I; Cristobal E; Pérez-Mies B; Rosa-Rosa JM; Gutierrez-Pecharroman A; Caniego-Casas T; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; García Á; Ibarra J; Hakim S; Guarch R; López-Guerrero JA; Poveda A; Palacios J
    Am J Surg Pathol; 2020 May; 44(5):649-656. PubMed ID: 32294063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma.
    Chow RD; Michaels T; Bellone S; Hartwich TMP; Bonazzoli E; Iwasaki A; Song E; Santin AD
    Cancer Discov; 2023 Feb; 13(2):312-331. PubMed ID: 36301137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.